NCT03619694

Brief Summary

In order to come as close as possible to the correct diagnosis of CNS tumors, MRI is the long-standing accepted method of choice that can in some cases be supported by the use of CT to demonstrate calcification or bone destruction. In individual cases MRI spectroscopy can be helpful for the differentiation between neoplasms and inflammatory lesions or surveillance of tumor therapy, just as perfusion

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Sep 2017

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2017

Completed
11 months until next milestone

First Submitted

Initial submission to the registry

August 3, 2018

Completed
5 days until next milestone

First Posted

Study publicly available on registry

August 8, 2018

Completed
24 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2018

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2018

Completed
Last Updated

August 8, 2018

Status Verified

August 1, 2018

Enrollment Period

1 year

First QC Date

August 3, 2018

Last Update Submit

August 3, 2018

Conditions

Brain Neoplasms

Outcome Measures

Primary Outcomes (1)

  • Comparison of MRS findings with the pathology of the specimens

    Analysis of the MRS metabolites peaks and integral and test if they can differentiate the grades of brain tumors

    Baseline

Interventions

MRI SpectroscopyDEVICE

Patient with brain SOL underwent MRI Spectroscopy to be compared with later pathology

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with brain tumors diagnosed by conventional imaging

You may qualify if:

  • All patients with space-occupying lesions

You may not qualify if:

  • Post operative cases
  • Non-neoplastic nature

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Assiut University

Asyut, Egypt

RECRUITING

Related Publications (2)

  • Peitgen N, Papanagiotou P. [Intra-axial brain tumors in adults : On the basis of the 2016 WHO classification]. Radiologe. 2017 Sep;57(9):707-714. doi: 10.1007/s00117-017-0271-6. German.

    PMID: 28667395BACKGROUND

  • Brindle KM, Izquierdo-Garcia JL, Lewis DY, Mair RJ, Wright AJ. Brain Tumor Imaging. J Clin Oncol. 2017 Jul 20;35(21):2432-2438. doi: 10.1200/JCO.2017.72.7636. Epub 2017 Jun 22.

    PMID: 28640699BACKGROUND

MeSH Terms

Conditions

Brain Neoplasms

Interventions

Magnetic Resonance Spectroscopy

Condition Hierarchy (Ancestors)

Central Nervous System NeoplasmsNervous System NeoplasmsNeoplasms by SiteNeoplasmsBrain DiseasesCentral Nervous System DiseasesNervous System Diseases

Intervention Hierarchy (Ancestors)

Spectrum AnalysisChemistry Techniques, AnalyticalInvestigative Techniques

Central Study Contacts

Mohamed AbdelWahab, Msc

CONTACT

01148918822dr.assiut@gmail.com

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal investigator

Study Record Dates

First Submitted

August 3, 2018

First Posted

August 8, 2018

Study Start

September 1, 2017

Primary Completion

September 1, 2018

Study Completion

October 1, 2018

Last Updated

August 8, 2018

Record last verified: 2018-08

Locations

EG(1)